Bank Julius Baer & Co. Ltd, Zurich Intercept Pharmaceuticals, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	SELL	$12.21 - $19.7 $109 - $177	-9 Reduced 1.65%	536 $7,000
Q4 2021 Feb 15, 2022	SELL	$14.28 - $19.53 $3,855 - $5,273	-270 Reduced 33.13%	545 $9,000
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $181 - $286	14 Added 1.75%	815 $12,000
Q2 2021 Jul 23, 2021	SELL	$15.46 - $24.5 $216 - $343	-14 Reduced 1.72%	801 $16,000
Q1 2021 May 10, 2021	BUY	$19.33 - $37.75 $96 - $188	5 Added 0.62%	815 $19,000
Q4 2020 Feb 24, 2021	SELL	$24.48 - $42.47 $52,509 - $91,098	-2,145 Reduced 72.59%	810 $20,000
Q4 2020 Feb 12, 2021	BUY	$24.48 - $42.47 $52,387 - $90,885	2,140 Added 262.58%	2,955 $20,000
Q3 2020 Nov 10, 2020	SELL	$39.09 - $53.44 $20,717 - $28,323	-530 Reduced 39.41%	815 $34,000
Q2 2020 Aug 12, 2020	BUY	$46.7 - $92.04 $46 - $92	1 Added 0.07%	1,345 $64,000
Q1 2020 May 13, 2020	BUY	$48.35 - $118.68 $64,982 - $159,505	1,344 New	1,344 $85,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.